the Japan Diabetes Society (JDS) and the Japanese Cancer Association (JCA) recently published a report 3 to address this issue, which reviewed evidence concerning the association between diabetes and cancer incidence or prognosis, risk factors in common to diabetes and cancer, their postulated biologic links, and the influence of diabetes treatments on the risk of cancer.
Epidemiology
Several meta-analyses have demonstrated that diabetes is associated with increased risks of cancer mortality and cancer incidence including site-specific cancers of the liver, endometrium, pancreas, kidney, colorectum, bladder, and breast ( Table 1) . Exceptionally, the risk of prostate cancer in diabetes is significantly decreased. It is also suggested that diabetic patients have a higher risk of cancer death than non-diabetic people (Tables 1  and 2) . [3] [4] [5] Furthermore, cancer patients with preexisting diabetes reportedly have higher short-term 14 and long-term 15 mortalities. 
Hyperglycemia
Hyperglycemia has been demonstrated to promote cancer development and cancer metastasis in type 2 diabetes. 22 In addition, hyperglycemia itself may promote carcinogenesis by generating oxidative stress. 23 The increase in oxidative stress would damage DNA, the initial step in carcinogenesis. The results of our study 16 support this hypothesis, because the results showed that the risk of both cancer incidence and mortality is also generally higher among Japanese 4 and Korean 24 subjects with diabetes, who have been deemed to be insulinopenic. 25 
Confounding bias
Observational analyses should be interpreted with caution. Potential risk factors to cancer and diabetes in common need to be addressed as potential confounders because it remains to be clarified whether the association between diabetes and the risk of cancer is mainly due to shared risk factors ( 
Insulin, sulfonylureas and glinides
As discussed earlier, injected insulin potentially increase the risk of cancer. In fact, several reports based on observational studies suggested that insulin glargine usage might be associated with an elevated risk of cancer. [27] [28] [29] [30] However, these observational studies were subject to considerable biases: retrospective studies only demonstrate an association and not necessarily causality; it is very difficult to adjust all possible confounders in observational studies; the effects of treatment by indication and informative censoring cannot be excluded. On the other hand, the oncogenic effect of hyperinsulinemia might be offset by the cancer-protective effect through amelioration of hyperglycemia. Randomized-controlled trials (RCTs) and more recent cohort studies have not indicated significant associations of insulin with cancer risk [31] [32] [33] and the causality is now practically negated. Sulfonylureas and glinides induce hyperinsulinemia and there is a concern of increased cancer risks.
However, the estimate in a meta-analysis of the cancer risk of sulfonylureas is neutral. 34 Data for glinides are limited and further investigations are needed to evaluate their oncogenic safety.
Metformin
Our recent meta-analysis including observational studies and RCTs suggested that metformin users have a lower risk of cancer incidence and mortality 35 ( Table 4 ) although bias could not be entirely eliminated. Metformin activates activating adenosine 5A-mono-phosphate-activated protein kinase (AMPK) through LKB-1, a tumor suppressor protein kinase.
AMPK, mammalian target of rapamycin (mTOR) and insulin-signaling pathway represent three interrelated components of a complex mechanism controlling cell responses to nutrient availability. AMPK inhibits protein synthesis and gluconeogenesis during cellular stress and inhibits mTOR, a downstream effector of growth factor signaling, which is frequently activated in malignant cells. To support the hypothesis of these direct effects, metformin potentiated the effect of neoadjuvant chemotherapy in early-stage breast cancer, 36 decreased the risk of colorectal cancer in a small RCT involving non-diabetic subjects, 37 and was associated with a decreased cancer risk while another insulin-sensitizer, thiazolidinediones, was not. 38 An animal study suggested that metformin prevented smoking-related lung cancer in mice, probably by inducing some hormone from the liver. 39 There are more recent meta-analyses supporting this potential benefit of metformin [40] [41] [42] [43] and several prospective clinical trials to evaluate its safety and efficacy are currently ongoing.
Pioglitazone
Recent reports including meta-analyses have suggested that it might be associated with an increased risk of bladder cancer in a exposure/dose-response pattern. 44, 45 The carcinogenic effect was also seen in an animal study 46 although the mechanism is not clarified yet. The causality is not conclusive at present 47 and several surveys are in progress. It is currently out of market in some countries because of this potential harm and it is prudent to follow its latest warning label.
¡-Glucosidase inhibitors
Data on the cancer risk associated with ¡-glucosidase inhibitors are sparse and highly biased. Cancer risk associated with ¡-glucosidase inhibitors remains inconclusive.
48-51
Glucagon-like peptide (GLP)-1 analogues and dipeptidyl peptidase (DPP-4) inhibitors It was initially reported that the risk of pancreas cancer and thyroid cancer was elevated among GLP-1 analogue users. 52 The risk of pancreas cancer was possibly increased with a DPP-4 inhibitor. 52 Although a meta-analysis suggested an oncogenic safety of DPP-4 inhibitors, 53 the included studies were of short follow-up periods and the long-term effect remains elusive. More recent RCTs have not demonstrated a significant risk of cancer.
54,55
Sodium glucose co-transporter (SGLT) 2 inhibitors
Long-term data on the oncogenic risk/safety in relation to these novel medications are lacking at present.
Conclusion
The present review underscores the need of more attention directed to elucidating the association between diabetes and cancer, which is pivotal for making timely, rational and informed decisions, not only in the areas of public health and economy, but also for the prevention and targeted management of these diseases in clinical practice. 
